Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 27.7%

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 141,200 shares, an increase of 27.7% from the December 31st total of 110,600 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average trading volume of 95,500 shares, the short-interest ratio is presently 1.5 days.

Aileron Therapeutics Stock Performance

The firm has a 50-day moving average of $2.52 and a 200-day moving average of $2.80. Aileron Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $7.42.

Institutional Investors Weigh In On Aileron Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. KG&L Capital Management LLC acquired a new stake in shares of Aileron Therapeutics during the third quarter worth about $46,000. Geode Capital Management LLC lifted its holdings in Aileron Therapeutics by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after buying an additional 59,370 shares in the last quarter. Sigma Planning Corp boosted its position in Aileron Therapeutics by 68.3% in the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after buying an additional 86,185 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new position in shares of Aileron Therapeutics in the second quarter worth $4,925,000. 90.89% of the stock is owned by hedge funds and other institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).